A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease
Last Updated: Wednesday, May 17, 2023
Results from a phase I trial demonstrate that fostamatinib, a spleen tyrosine kinase inhibitor, has a manageable safety profile post alloHCT and an overall response rate of 77% in patients with steroid-refractory chronic GVHD.
Advertisement
News & Literature Highlights